...BRCA2. The BRCA1/2 HWA is based on the premise that pathogenic variants in these genes will be identified more often in ...
...BRCA2+) 7.2 to 12.9 years after RRSO (BRCA1: 0.18 expected [O:E ratio, 22.2; 95% CI, 6.1-56.9; P < .001]; BRCA2: 0.16 ex...
...BRCA2 mutations.,Between July 2013 and December 2015, 108 women with ovarian cancer were counselled and consented by nur...
...BRCA2 genetic testing. The care of women with BRCA-associated ovarian cancer should be tailored to their mutation status...
...BRCA2 and CDKN2A. Research into the identification of mutations in known cancer predisposition genes and through next-ge...
...BRCA2 mutations have been consistently shown to increase prostate cancer risk, and are more commonly observed among pati...
...BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BR...
...BRCA2, ATM, PALB2, CDH1, TP53, FANCM, CHEK2, MLH1, MSH2, MSH6 and PMS2. Prior genetic testing had demonstrated that thes...
...BRCA2. Other tumors defective in HRR, including some hematological malignancies, are predicted to be good candidates for...
...BRCA2, RAD51 and RAD52. The protein levels of γH2AX, RAD 51 and p53 were analyzed by Western blot.,Remarkable DNA strand...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
